Radioprotectin-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Radioprotectin-1 是 LPA2 的选择性激动剂，对鼠 LPA2 GPCR 的 EC50 为 25 nM，并发挥辐射防护和辐射缓解作用。

Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.(In Vitro):In MEF and IEC-6 cells expressing LPA2, Radioprotectin-1 (0, 0.1, 0.3, 1.0, and 3 μM) effectively reduces apoptosis induced by gamma-irradiation and the radiomimetic chemotherapeutic Adriamycin.(In Vivo):In C57BL/6 female mice, Radioprotectin-1 (0.1 and 0.3 mg/kg; s.c.) decreases the mortality in models of the hematopoietic and gastrointestinal acute radiation syndrome.

Radioprotectin-1 is a potent agonist of LPA2 with an EC50 of 5 pM and functions as a full agonist at the human ortholog of LPA2.Radioprotectin-1 (0-3 μM; 15 minutes) effectively reduces apoptosis induced by γ-irradiation and the radiomimetic drug Adriamycin in cells that expressed LPA2 either endogenously or after transfection. Cell Viability Assay Cell Line:MEF cells , IEC-6 cells Concentration:0 μM, 0.1 μM, 0.3 μM, 1.0 μM,3 μM Incubation Time:15 minutes Result:Protected cells from apoptosis by γ-irradiation- and the radiomimetic chemotherapeutic Adiamycin.

Radioprotectin-1 is a high-potency specific agonist of the murine LPA2 GPCR .Radioprotectin-1 (0.1 mg/kg, 0.3 mg/kg; s.c.; every 12 hours; for 3 days) decreases the mortality of C57BL/6 mice in models of the hematopoietic acute radiation syndromes (HE-ARS) and gastrointestinal acute radiation syndromes (GI-ARS) .Radioprotectin-1 exerts its radioprotective and radiomitigative action through specific activation of the upregulated LPA2 GPCR in Lgr5+stem cells. Animal Model:8-10 weeks old C57BL/6 female mice bearing total body irradiation (TBI) Dosage:0.1 mg/kg, 0.3 mg/kg Administration:Subcutaneous injection; every 12 hours; for 3 days Result:Decreased mortality of C57BL/6 mice in models of the HE-ARS and the GI-ARS.

5-chloro-2-[4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butylsulfamoyl]benzoic acid | Radioprotectin 1

GPCR/G Protein

LPA Receptor

——

——

——

1622006-09-0

486.92

C23H19ClN2O6S

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (256.72 mM)

OC(=O)c1cc(Cl)ccc1S(=O)(=O)NCCCCN1C(=O)c2cccc3cccc(C1=O)c23

——

(-20℃)

With Ice Pack

≥ 2 years